


34. BraundwaldFauci; Kasper; Hauser; Longo, Jamesson“Harrison’s, Principals of Internal Medicine”, **15th** edition, vol-1.


38. cancerquest@emory.edu.


140. Konner, J.A.; et al. "A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. 2007.


260. Vispe, S.; Devries, L.; Creancier, L. *et al.* Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Molecular Cancer Therapy. **2009**.

261. Vosberg, H.P. DNA topoisomerases: enzymes that control DNA conformation. In Current Topics in Microbiology and Immunology. **1985**.


267. WHO Cancer ( http://www.who.int/mediacentre/factsheets/fs297/en/)


270. Xiang jian Luo, Xin fang Yu, Sufang Liu, Qipan Deng, Xiaolan Liu, Songling Peng, Hongde Li, Jikai Liu and Ya Cao. The role of targeting kinase activity by natural products in cancer chemoprevention and chemotherapy (Review). Oncology reports. 2015, 34: 547-554.


